Immune phenotype in children with therapy-naïve remitted and relapsed Crohn’s disease

Figure 1 Prevalence of cellular members of adaptive immunity. The prevalence of activated (i.e. CD4⁺CD25⁺) (A), effector or memory (i.e. CD4⁺CXCR3⁺) (B), Th1 committed (i.e. CD4⁺CXCR3⁺) (C) and regulatory T (i.e. CD4⁺CD25hiFoxP3⁺) cells (D). ^aP < 0.05, ^bP < 0.01, ^dP < 0.001 vs control; ^cP < 0.05, ^fP < 0.01 vs therapy-naïve; ^eP < 0.05, ^hP < 0.01 vs relapse.

Figure 2 Prevalence of cellular members of innate immunity. The prevalence of natural killer T (i.e. CD3⁺6b11⁺) (A), natural killer (i.e. CD3^-CD161⁺) (B), dendritic cell (i.e. Lin1-HLA-DR⁺) (C), peripheral monocyte (i.e. CD14⁺) (D), Toll-like receptor 2 expressing dendritic cell (E) and Toll-like receptor 4 expressing dendritic cell (F). ^aP < 0.05, ^bP < 0.01, ^dP < 0.001 vs control; ^cP < 0.05, ^fP < 0.01 vs therapy-naïve; ^eP < 0.05 vs first remission; ^gP < 0.05 vs relapse.